Torudokimab Biosimilar - Research Grade

Human

IL33

>1mg/ml

Human IgG4 - kappa

CHO Cells

Etokimab Biosimilar - Research Grade (ICH5061), Itepekimab Biosimilar - Research Grade (ICH5249), Tozorakimab Biosimilar - Research Grade (ICH5938)

https://www.imgt.org/mAb-DB/

ICH3002

O95760

Blue ice

This product is a research-grade biosimilar of torudokimab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is built around the interleukin-33 (IL-33) target and reproduces the antigen-binding specificity of the originator as a human IgG4-kappa molecule, without any therapeutic labeling or clinical intent. It is manufactured to in-vivo research standards with low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg where offered) and is available in bulk milligram-to-gram quantities suitable for functional and comparability studies. As a biosimilar rather than a hybridoma-derived antibody, it is defined by its molecular sequence and target engagement rather than by a clone designation. Typical applications include serving as an IL-33-neutralizing reference reagent, a positive control in binding and blocking assays, and a benchmarking tool alongside other anti-IL-33 reagents. Because torudokimab is directed against a human target, this reagent is primarily intended for in-vitro and functional characterization rather than routine mouse in-vivo dosing. Content here is provided for ichor.bio to review. Interleukin-33 (IL-33; UniProt O95760) is an IL-1 family cytokine and a nuclear-associated alarmin constitutively expressed by epithelial and endothelial cells at barrier surfaces. Upon cell damage or stress, IL-33 is released into the extracellular space, where it signals through the ST2 receptor (IL1RL1) together with the IL-1 receptor accessory protein, driving MyD88-dependent activation of NF-kB and MAPK pathways. This axis is a major amplifier of type 2 immunity, activating ILC2s, mast cells, eosinophils, and Th2 cells and promoting production of IL-5 and IL-13. IL-33/ST2 signaling is strongly implicated in asthma and allergic airway inflammation, atopic dermatitis, and other type 2-driven and fibrotic conditions, making IL-33 an actively pursued therapeutic target. Torudokimab binds IL-33 and is intended to neutralize its interaction with ST2.

Interleukin-1 family member 11, IL-1F11, Nuclear factor from high endothelial venules, NF-HEV, Interleukin-33, C9orf26

Detects human IL33

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

4 weeks